Is prostate cancer different in black men? Answers from 3 natural history models by Tsodikov, A et al.
1 
 
Title: Is prostate cancer different in black men? Answers from three natural history 
models 
Running title: Prostate cancer in black men 
Keywords: cancer epidemiology; mass screening; prostatic neoplasms; prostate-specific 
antigen; racial disparities; statistical methods and models 
Authors: Alex Tsodikov1, PhD; Roman Gulati2, MS; Tiago M. de Carvalho3, MS; Eveline A. 
M. Heijnsdijk3, PhD; Rachel A. Hunter-Merrill2, MA; Angela B. Mariotto4, PhD; 
Harry J. de Koning3, MD; Ruth Etzioni2, PhD 
Affiliations: 1Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA 
2Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
Seattle, WA, USA 
3Division of Public Health, Erasmus University Medical Center, Rotterdam, The 
Netherlands 
4Division of Cancer Control and Population Sciences, National Cancer Institute, 
Bethesda, MD, USA 
Correspondence: Ruth Etzioni, Division of Public Health Sciences, Fred Hutchinson Cancer 
Research Center, 1100 Fairview Ave N, M2-B230, Seattle WA 98109-1024, USA. 
Tel: +1.206.667.6561. Fax: +1.206.667.7264. Email: retzioni@fredhutch.org 
Funding: This work was made possible by Grant Numbers U01 CA157224 and U01 
CA199338 from the National Cancer Institute as part of the Cancer Intervention 
and Surveillance Modeling Network (CISNET). Its contents are solely the 
responsibility of the authors and do not necessarily represent the official views 
of the National Cancer Institute. 
Disclosures: EAMH and HJK received a research grant from Beckman Coultier. All other 
authors declare no potential conflict of interest. 
Lengths: 20 pages, 3 figures, 2 tables 
Precis: We apply three models to study differences in prostate cancer natural history 
between black men and the general US population. We find black men have 
higher prevalence of preclinical disease at all ages and higher risk of metastasis, 
supporting further study into different screening policies for blacks. 
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Abstract 
Background: Black men in the US have substantially higher prostate cancer incidence rates than the 
general population. The extent to which the incidence disparity is due to prostate cancer being more 
prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. 
 
Methods: We estimated three independently developed models of prostate cancer natural history in 
black men using an updated reconstruction of PSA screening, based on the National Health Interview 
Survey in 2005, and prostate cancer incidence from the Surveillance, Epidemiology, and End Results 
program in 1975–2000. Using the estimated models, we compared summary measures of prostate 
cancer natural history in black men and in the general population. 
 
Results: The models projected that 29–45% (range across models) of black men develop preclinical 
prostate cancer in their lifetime, a risk that is (relatively) 24–54% higher than in the general population. 
Among men who have had preclinical disease onset, black men have a similar risk of diagnosis compared 
with the general population, but their risk of progression to metastatic disease by the time of diagnosis 
is 38–58% higher than in the general population. 
 
Conclusions: Prostate cancer incidence patterns implicate substantially higher incidence of preclinical 
prostate cancer and a higher risk of metastatic progression among black men. The findings suggest 
screening black men earlier than white men and support further research into the benefit-harm 
tradeoffs of more aggressive screening policies for black men.  
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INTRODUCTION 
Prostate cancer is the most frequent cancer diagnosis and the second leading cause of cancer death in 
US men. Black men in the US have significantly higher prostate cancer incidence and mortality than 
white men, but reasons for this disparity are unclear. Some studies1 have suggested that differential 
access to care may partially explain the greater burden of disease in blacks, but others have concluded 
that differences in outcomes are more plausibly attributed to biologic differences.2-4 Black race has been 
associated with higher prostate-specific antigen (PSA) levels at diagnosis5-7 and a higher risk of 
recurrence following radical prostatectomy after controlling for other clinical and demographic 
characteristics.8-10 
  
There is no question that the higher prostate cancer mortality in black men is at least partially due to 
their increased incidence of disease.11 What is not known, however, is whether the higher observed 
incidence in black men arises from a higher risk of disease onset or faster progression to an aggressive 
or symptomatic state. In their multi-ethnic study of UK men, Metcalfe et al.12 suggest that the latter is 
unlikely; however, they do not formally interrogate this hypothesis.  
 
Understanding whether and how natural history might be different in black men is important because if 
black men have a higher susceptibility to prostate cancer and/or a greater tendency to develop 
aggressive disease, it may be of value to consider different screening policies for them. This issue was 
raised by Powell et al.,13 who recommended aggressive screening of black men beginning at age 40 
based on a narrowing of prostate cancer survival disparities observed following the adoption of PSA 
screening in the US. 
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We previously studied the natural history of prostate cancer in the general population via statistical and 
computer modeling of latent disease onset and progression to clinical and metastatic states.14-16 By 
calibrating the models to observed population patterns of prostate cancer incidence before and after 
the advent of PSA screening, we estimated the risks of critical events in disease natural history and used 
these results to make inferences about potential impacts of different screening policies.17, 18 
 
In this article, we develop versions of our natural history models that pertain to black men and calibrate 
these using incidence trends in the Surveillance, Epidemiology, and End Results (SEER) program under 
updated PSA screening frequencies estimated specifically among the black population. We use the 
calibrated models to produce estimates of disease onset, progression, and diagnosis risks that pertain to 
the black population. We compare these risks with our estimates for the general population (i.e., all 
races) to determine the extent to which the increased incidence among black men is explained by higher 
risks of disease onset, progression, or diagnosis. We also provide natural history summaries, including 
lifetime risks of disease onset, post-onset progression, and detection, for black men compared with the 
population as a whole. Finally, we use our results to motivate consideration of differential screening 
policies among black men. 
 
METHODS 
In this section, we describe the data and three models that we use to examine evidence of differential 
prostate cancer natural history in black men. We also describe a test for differences in black natural 
history relative to the general population and quantify the models’ goodness-of-fit after re-estimating 
key components of natural history. 
 
PSA screening and prostate cancer incidence data 
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Because population-based PSA screening utilization was not tracked in real time, we retrospectively 
reconstructed PSA screening patterns in the US separately for black and white men in a previous study.19 
Briefly, this reconstruction used responses to the National Health Interview Survey (NHIS) in 2000 to 
estimate the age at first PSA test, and longitudinal claims data from the linked SEER-Medicare database 
to estimate the distribution of inter-screening intervals. We updated the resulting model of PSA 
screening patterns using responses to the NHIS in 2005, which moderately reduced the uptake of first 
PSA tests in the 1990s among the oldest age groups relative to our previous analysis.19 
 
We extracted prostate cancer incidence data from the SEER database before and after the introduction 
of PSA screening. Specifically, we extracted prostate cancer incidence for ages 50–84, years 1975–2000, 
SEER historic stages local-regional and distant, tumor grade well or moderately differentiated (low-
grade) versus poorly differentiated or undifferentiated (high-grade), and race categories “black” or “all 
races.” Missing information on stage, grade, and race was assumed to be missing at random and 
imputed as the most frequent combination of 20 logistic regression imputations using the mice package 
in R.20 
 
Three models of prostate cancer natural history 
We estimated three models of prostate cancer natural history using PSA screening and prostate cancer 
incidence data separately for black men and for all races. The three models were previously used to 
study effects of PSA screening on incidence and mortality trends in the general US population.21, 22 
 
Briefly, the FHCRC model is a microsimulation model that links individual PSA growth and cancer 
progression. In this model, higher and increasing PSA levels are associated with the presence of latent 
cancer and shorter intervals to metastatic spread and clinical presentation. The MISCAN model is a 
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microsimulation model that tracks progression through combinations of cancer stages and grades. In 
this model, advanced stages and higher grades are associated with potentially higher screening test 
sensitivity and shorter intervals to clinical presentation. The UMICH model is an integrated suite of 
analytic models that estimates transition probabilities from earlier to later stages and from lower to 
higher grades during the preclinical detectable phase. In this model, a later stage at onset, a higher 
grade at onset, and faster progression are each associated with shorter intervals to clinical presentation. 
In each model, screening potentially detects latent cancer at an earlier stage and/or grade. Key 
differences between models are the length of the preclinical detectable phase, how much early 
detection improves tumor characteristics, and how both natural history and screening effects depend on 
age. Detailed descriptions of the models are given in the Appendix. 
   
A framework to explain incidence disparities 
Sequential estimation 
We first re-estimated natural history in all races using the SEER incidence and updated PSA screening 
data. Then, we re-estimated natural history in black men following a systematic sequence of steps. First, 
we substituted PSA screening patterns for black men. Then we re-estimated components of disease 
natural history, each containing a specific block of parameters. The blocks of parameters governed (a) 
risk of disease onset and initial tumor features, (b) risks of progression to metastasis and/or high-grade 
disease, and (c) risk of clinical diagnosis. At each step, the re-estimation involved identifying values of 
the natural history parameters that allowed the models to most closely match SEER prostate cancer 
incidence in black men. All models proceeded in this sequential fashion until final versions of the models 
were obtained that re-estimated all natural history parameters for black men. 
 
Natural history summary measures 
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Given the final versions of the models for black men and for all races, we summarized natural history in 
terms of lifetime risks of preclinical onset, post-onset progression, and clinical diagnosis; mean ages at 
these natural history events; and mean years between consecutive events. 
 
Testing and quantifying contributions to incidence disparities 
We used a likelihood ratio test to evaluate whether re-estimating components of disease natural history 
significantly improved the models’ fits to the incidence data for black men. The likelihood uses age at 
diagnosis as a survival time and is fit via a customized age-period approach.16 To calculate likelihood 
ratio statistics, two likelihood functions are fit, one with and one without re-estimation of the 
component. While we report the likelihood ratio test results, we anticipate that, given the large sample 
size in the SEER registry, all tests will be highly significant at a traditional threshold. Therefore, we also 
report the improvement in the goodness-of-fit achieved by re-estimating components of natural history, 
with goodness-of-fit expressed as the sum across years of the squared difference between annual 
model-projected and observed age-adjusted incidence rates. 
 
RESULTS 
Figure 1 illustrates the annual percentage of men ages 50–84 who received at least 1 PSA test by race 
and age group over the period 1988–2000 using responses from the NHIS in 2005. Relative to previous 
estimates using responses from the NHIS in 2000,19 we find that younger men received more tests, 
particularly in the late 1990s, and older men received fewer tests; these differences were similar among 
black men and all races. The updated screening patterns indicate that, relative to the general 
population, modestly lower percentages of black men received at least 1 PSA test in all but the youngest 
ages throughout the 1990s. The greatest racial disparities in PSA testing were in the oldest ages. 
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Figure 2 shows the results of re-estimating natural history for all races. The figure shows age-adjusted 
prostate cancer incidence rates per 100,000 men ages 50–84 reported in SEER by historic stage and 
corresponding model-projected incidence rates. Figure 2 also shows SEER incidence rates for black men 
and results of the sequential estimation of the models’ natural history components. The sequential 
estimation found that allowing the risk of disease onset to be different for black men provided an 
immediate improvement in the models’ fits to incidence in this population. Allowing the risk of 
progression to distant stage to be different produced higher distant-stage but similar local-regional 
stage incidence projections.  And allowing the risk of progression to clinical diagnosis to differ provided 
modest improvements to the fit in some cases (e.g., distant-stage incidence in the FHCRC model).  
 
Improvements from re-estimating each block of natural history parameters were highly statistically 
significant from likelihood ratio tests (all p-values < 0.0001), and the final models’ fits to stage-specific 
incidence were substantially improved by re-estimation of the natural history components. Table 1 
shows that sums of squared differences between observed and projected age-adjusted incidence rates 
declined dramatically once disease onset was re-estimated, confirming the importance of disease onset 
risk in explaining incidence disparities. All models obtained the best fits (i.e., smallest errors) when all 
parameter blocks were re-estimated, though the UMICH fit was similar after re-estimating diagnosis. 
 
Table 2 summarizes natural history measures among black men and for all races estimated by the three 
final models. In the general population, the lifetime risk of developing preclinical disease is 23–29% 
(range across models). In black men, however, these risks rise to 29–45%, reflecting risks that are 
(relatively) 24–54% higher than the general population. According to the models, the risk of clinical 
diagnosis is 25–66% higher than the general population; the corresponding observed risk in SEER prior 
to the advent of PSA screening was 53% higher in black men than white men (range 42%–62% higher) 
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over the period 1975 to 1986. Among men who have had disease onset, the risk of clinical diagnosis is 
comparable for blacks (39–85% across models) and all races (36–86% across models), and this translates 
into sojourn times from disease onset to diagnosis that are very similar for black men and the general 
population. However, among men with preclinical disease, the models estimate a 38–58% higher risk of 
metastasis before diagnosis among black men, reflecting greater risk of progression in this population. 
 
DISCUSSION 
The observation that prostate cancer is more is more frequent and more lethal among black men than 
among white men has never been fully explained. Our study uses three models14-16 previously calibrated 
to US population incidence trends. After updating the frequency of PSA testing and re-estimating these 
models for all races, we substituted PSA testing frequencies observed among black men into the models 
for all races and then systematically explored re-estimating individual components of disease natural 
history to fit disease incidence patterns in this population. The model results consistently showed that 
the risk of onset of a preclinical prostate cancer explains a large majority of the observed incidence 
disparities. Additional improvements achieved by re-estimating other natural history components 
produced moderate additional improvements in reproducing overall observed incidence among black 
men but yielded noticeable improvement in reproducing observed advanced-stage incidence. 
Estimation of natural history summaries based on the full race-specific models confirmed that, in 
addition to the risk of onset, the risk of progression to metastatic disease before clinical diagnosis was 
higher among black men, but the risk of progression to clinical diagnosis was not higher than in the 
general population. 
 
Based on these results, we conclude that black men have more preclinical and progressive prostate 
cancer than the general population. They are more likely to develop prostate cancer at a younger age, 
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and they are more likely to progress to a metastatic state and/or higher grade before clinical diagnosis. 
Their higher risk of progression agrees with a previous study based on autopsy and surgical pathology 
data4 that concluded that black men had an earlier transformation to clinically significant cancer than 
white men. This study found similar age-specific prevalence of prostate cancer among autopsies 
conducted in black and white men from the Detroit metropolitan area between 1992 and 2001. The 
study also found evidence of more aggressive disease in radical prostatectomy specimens from black 
men, consistent with their markedly higher incidence of metastatic disease at diagnosis. These findings 
led the authors to conclude that the risk of prostate cancer initiation did not differ by race, but the risk 
of disease progression was higher among black men. However, similar latent prevalence and greater 
metastatic clinical incidence of disease among black men is in fact only possible if latent incidence is also 
higher in this subgroup. For, if latent incidence is similar among black men but progression is faster, this 
would actually lead to lower latent prevalence at autopsy. Therefore, we conclude that the prior study 
results are in fact consistent with our finding that the risks of latent incidence and progression are likely 
both higher among black men. 
 
Our findings motivate explicitly considering more intensive screening, e.g., beginning earlier and/or 
screening more frequently among black men than among the general US population. Figure 3 shows the 
cumulative incidence of “relevant disease,” i.e., disease fated to present before other-cause death. At all 
ages, the cumulative incidence is higher for black men than for all races. At ages 46–52 (range across 
models), the cumulative incidence among black men reaches the value estimated at age 55 among all 
races. Thus, if it is agreed that prostate cancer screening is worthwhile, and starting at age 55 is 
determined for the general population, our results suggest starting around age 46-52 for black men.  
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We recognize that a consensus about general population screening is still lacking. The US Preventive 
Services Task Force23 recommends against routine prostate cancer screening in men of average risk, 
while the American Cancer Society24 recommends shared decision making around prostate cancer 
screening beginning at age 50 and the American Urological Association25 provides similar guidance with 
a starting age of 55. However, black men are not average risk and the benefit-harm tradeoffs of 
screening are likely to be different for this population.26 
 
While starting at an earlier age is unlikely to impact overdiagnosis, other more aggressive screening 
policies, e.g., shortening intervals between screens or lowering the PSA threshold for biopsy referral, 
could increase risks of overdiagnosis.27 A comprehensive policy development process addressing 
whether and how best to screen black men will have to carefully weigh benefit-harm tradeoffs of 
candidate policies. Understanding race-specific natural history will be a critical pre-requisite for this 
important work. At this point, however, our findings do support starting screening at an earlier age in 
black men than in the general population. Powell et al.13 also recommend aggressive early prostate 
cancer PSA testing of African American men. Our work adds to theirs by providing a formal, quantitative 
justification for an age to initiate screening in black men. 
 
In practice, the policy development process will require going beyond examining incidence patterns to 
projecting mortality in the presence and absence of screening. Since screening benefit is contingent on 
access to efficacious therapies, benefits of screening in different race groups may be affected by any 
disparities in access to treatment and any racial differences in treatment efficacy. Future work will 
extend the models used in this article to project the downstream outcomes of different screening 
policies in black men under race-specific treatment distributions and efficacies. 
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Limitations of this study relate primarily to modeling assumptions and data limitations. While the use of 
multiple models provides some sense of robustness to the specific assumptions made, all models 
assume that disease is progressive. Thus, none of the models explicitly includes an indolent 
subpopulation, although each allows heterogeneity of disease progression with some cases progressing 
rapidly and others slowly. The FHCRC model allows the likelihood of developing high-grade disease to 
vary with age but does not model grade progression; the other models allow both grade and stage 
progression. Other differences across models are also driven by differences in the conceptualization of 
onset and how the risk of onset depends on age. In the FHCRC model, onset refers to the latent 
incidence of disease that would be detectable by biopsy, which can occur as early as age 35, while in the 
MISCAN and UMICH models onset refers to the latent incidence of disease that can be detected based 
on elevated PSA and diagnostic workup, and this occurs rarely before age 40. Finally, the PSA screening 
rates used by all the models are based on a retrospective reconstruction rather than a prospective 
tracking of prostate cancer screening dissemination in the US population. 
 
In conclusion, this study represents the first examination of how prostate cancer natural history must 
differ in black men to account for racial variation in patterns of disease incidence before and after the 
advent of PSA screening. We use observed patterns of disease incidence and screening to learn about 
key events in the latent process of disease by race. Our results provide quantitative information about 
the prostate cancer natural history that may justify exploring different screening policies among white 
and black men. In pursuit of policies that will reduce disparities in disease outcomes, it may ultimately 
be necessary to intervene with greater intensity among population subgroups at highest risk.  
13 
 
Figure 1. Annual percentage of men receiving at least 1 PSA test based on the updated reconstruction of 
PSA screening patterns in the US. 
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Figure 2. Age-adjusted prostate cancer incidence rates per 100,000 men ages 50–84 years for black men 
(black line) and all races (gray line) and corresponding projections by three models (colored lines). 
Model projections are based on the models estimated for all races combined with PSA screening in black 
men and sequentially re-estimating components of natural history to allow differential risk of onset of 
preclinical cancer (“Onset”), risk of progression to metastasis and/or higher grade (“Onset-
Progression”), and risk of clinical diagnosis (“Onset- Progression -Diagnosis”). 
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Figure 3. Cumulative incidence of onset of preclinical prostate cancer that would be clinically diagnosed 
in black men and all races projected by the models. Line segments show ages at which black men have 
incidence corresponding to levels estimated at age 55 in all races. 
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Table 1. Squared differences between age-adjusted prostate cancer incidence rates per 100,000 men 
ages 50–84 years for black men and corresponding model projections, summed across years 1975–2000. 
Model projections are based on the models estimated for all races combined with PSA screening in black 
men (“Black screening”) and sequentially re-estimating components of natural history to allow 
differential risk of onset of preclinical cancer (“Onset”), risk of progression to metastasis and/or higher 
grade (“Onset-Progression”), and risk of clinical diagnosis (“Onset-Progression-Diagnosis”). 
Run FHCRC MISCAN UMICH 
Black screening 287160 271140 127130 
Onset 41130 18340 136110 
Onset-Progression 121280 23180 120650 
Onset-Progression-Diagnosis 39250 18670 122780 
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Table 2. Natural history summary measures for black men (Blacks) and for all races (All) projected by the 
three models. Lifetime risks are given as percentages; mean ages and durations are given in years. 
Measure 
FHCRC MISCAN UMICH 
Blacks All Blacks All Blacks All 
Lifetime risk of onset 45 29 31 25 29 23 
Lifetime risk of clinical diagnosis 17 10 15 12 25 20 
Lifetime risk of metastatic clinical diagnosis 5 2 4 3 5 3 
Lifetime risk of clinical diagnosis given onset 39 36 48 47 85 86 
Lifetime risk of metastatic clinical diagnosis given onset 10 6 14 10 17 12 
Mean age at onset 58 60 65 68 67 70 
Mean age at clinical diagnosis 73 74 72 74 74 77 
Mean age at metastatic clinical diagnosis 73 75 73 76 73 75 
Mean years from onset to clinical diagnosis 19 18 10 10 3 3 
Mean years from onset to metastatic clinical diagnosis 16 16 12 13 6 8 
Lifetime risk of PSA or clinical diagnosis* 18 11 20 17 26 20 
Lifetime risk of PSA or clinical diagnosis given onset* 41 39 66 68 88 85 
Mean age at PSA or clinical diagnosis* 72 73 70 72 72 75 
Mean years from PSA to clinical diagnosis* 7 7 8 9 4 4 
* These measures are in the presence of modeled PSA screening patterns in 1987–2000 and are included for reference.  
18 
 
References 
1. Underwood W, 3rd, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG. Postprostatectomy cancer-free 
survival of African Americans is similar to non-African Americans after adjustment for baseline cancer 
severity. Urol Oncol. 2004;22: 20-24. 
2. Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ET, Taylor JA. Genetic polymorphism and prostate 
cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and 
European-Americans. Prostate. 2013;73: 11-22. 
3. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. Journal of 
Urology. 2007;177: 444-449. 
4. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier 
transformation to clinically significant prostate cancer in black than in white American men, and 
influences racial progression and mortality disparity. Journal of Urology. 2010;183: 1792-1796. 
5. Smith DS, Bullock AD, Catalona WJ, Herschman JD. Racial differences in a prostate cancer screening 
study. Journal of Urology. 1996;156: 1366-1369. 
6. Tewari A, Horninger W, Badani KK, et al. Racial differences in serum prostate-specific antigen (PSA) 
doubling time, histopathological variables and long-term PSA recurrence between African-American and 
white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 
2005;96: 29-33. 
7. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference 
ranges for prostate-specific antigen in black men. New England Journal of Medicine. 1996;335: 304-310. 
8. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for 
prostate cancer recurrence following radical prostatectomy in an equal access health care setting. 
Journal of Urology. 1996;155: 1667-1673. 
19 
 
9. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity 
and race in men with prostate cancer undergoing radical prostatectomy. Journal of Clinical Oncology. 
2004;22: 439-445. 
10. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after 
radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate 
Strategic Urologic Research Endeavor databases. Journal of Urology. 2001;166: 1322-1327. 
11. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 
2012;118: 4280-4289. 
12. Metcalfe C, Evans S, Ibrahim F, et al. Pathways to diagnosis for Black men and White men found to 
have prostate cancer: the PROCESS cohort study. British Journal of Cancer. 2008;99: 1040-1045. 
13. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: 
evidence for aggressive early prostate cancer PSA testing of African American men. Cancer 
Epidemiology, Biomarkers and Prevention. 2014;23: 1505-1511. 
14. Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using 
population data: a critical precursor to policy development in cancer control. Biostatistics. 2010;11: 707-
719. 
15. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen 
screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. Journal of 
the National Cancer Institute. 2003;95: 868-878. 
16. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat in Med. 
2006;25: 2846-2866. 
17. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based 
prostate cancer screening strategies: Model estimates of potential benefits and harms. Annals of 
Internal Medicine. 2013;158: 145-153. 
20 
 
18. Heijnsdijk EA, de Carvalho TM, Auvinen A, et al. Cost-effectiveness of prostate cancer screening: a 
simulation study based on ERSPC data. Journal of the National Cancer Institute. 2015;107: 366. 
19. Mariotto A, Etzioni R, Krapcho M, Feuer EJ. Reconstructing prostate-specific antigen (PSA) testing 
patterns among black and white men in the US from Medicare claims and the National Health Interview 
Survey. Cancer. 2007;109: 1877-1886. 
20. van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations in R. Journal of 
Statistical Software. 2011;45: 1-67. 
21. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate 
cancer mortality decline. Cancer Causes and Control. 2008;19: 175-181. 
22. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes 
and prostate cancer mortality declines. Cancer. 2012;118: 5955-5963. 
23. Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force 
recommendation statement. Annals of Internal Medicine. 2012;157: 120-134. 
24. Wolf AM. American Cancer Society guideline for the early detection of prostate cancer: update 2010. 
CA Cancer J. Clin. 2010;60: 70-98. 
25. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. Journal of 
Urology. 2013;190: 419-426. 
26. Hall L, Bullock AD, Brown AL, Colditz G. Prostate Cancer Isn’t Colorblind. New York Times, 2016. 
27. Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate 
cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiology Biomarkers and 
Prevention. 2016. 
 
